record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
BIOMEDE phase 2 international trial, Nature Medicine
authors
reviewer:will-blair
BIOMEDE trial (N=233, diffuse intrinsic pontine glioma): None of three targeted-therapy arms (erlotinib, dasatinib, everolimus) + radiation exceeded radiotherapy alone on primary OS endpoint, revealing fundamental inadequacy of single-pathway inhibition in pediatric HGG.
vs_1a5f91868ccc2009 · manual_curation
outgoing
vf_4171b4670921b306BIOMEDE's mandatory profiling revealed co-mutation architecture absent in prior trials, explaining negative efficacy
incoming
supports · vf_9b4448c7d232846f
contradicts · vf_1823c24df2a66f27
events
vev_ab360e1c6d555c30finding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_0dac2db5f8628508finding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.